Heart Failure Drugs Industry Research Report 2023
This report aims to provide a comprehensive presentation of the global market for Heart Failure Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Heart Failure Drugs.
The Heart Failure Drugs market size, estimations, and forecasts are provided in terms of sales volume (MT) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Heart Failure Drugs market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Heart Failure Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2018-2023. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
Global markets are presented by Heart Failure Drugs type, along with growth forecasts through 2029. Estimates on sales and revenue are based on the price in the supply chain at which the Heart Failure Drugs are procured by the manufacturers.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows sales and revenue data by type, and during the historical period (2018-2023) and forecast period (2024-2029).
Heart Failure Drugs segment by Type
This report has provided the market size (sales and revenue data) by application, during the historical period (2018-2023) and forecast period (2024-2029).
This report also outlines the market trends of each segment and consumer behaviors impacting the Heart Failure Drugs market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Heart Failure Drugs market.
Heart Failure Drugs segment by Application
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2018-2029.
The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2021 because of the base year, with estimates for 2023 and forecast revenue for 2029.
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Heart Failure Drugs market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Reasons to Buy This Report
This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Heart Failure Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
This report will help stakeholders to understand the global industry status and trends of Heart Failure Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
This report stays updated with novel technology integration, features, and the latest developments in the market
This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Heart Failure Drugs industry.
This report helps stakeholders to gain insights into which regions to target globally
This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Heart Failure Drugs.
This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Core Chapters
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Heart Failure Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Heart Failure Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Heart Failure Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
The Heart Failure Drugs market size, estimations, and forecasts are provided in terms of sales volume (MT) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Heart Failure Drugs market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Heart Failure Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2018-2023. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
- Novartis
- Pfizer
- AstraZeneca
- Hikma
- Teva
- Cipla
- Merck & Co.
- Amgen
- Roche
- Sun Pharma
- Mylan
Global markets are presented by Heart Failure Drugs type, along with growth forecasts through 2029. Estimates on sales and revenue are based on the price in the supply chain at which the Heart Failure Drugs are procured by the manufacturers.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows sales and revenue data by type, and during the historical period (2018-2023) and forecast period (2024-2029).
Heart Failure Drugs segment by Type
- ACEI
- Angiotensin II Receptor Blockers
- ARNIs
- Beta Blockers
- Aldosterone Antagonists
- Diuretics
This report has provided the market size (sales and revenue data) by application, during the historical period (2018-2023) and forecast period (2024-2029).
This report also outlines the market trends of each segment and consumer behaviors impacting the Heart Failure Drugs market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Heart Failure Drugs market.
Heart Failure Drugs segment by Application
- Reduced Ejection Fraction
- Preserved Ejection Fraction
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2018-2029.
The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2021 because of the base year, with estimates for 2023 and forecast revenue for 2029.
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia
- China Taiwan
- Indonesia
- Thailand
- Malaysia
- Latin America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Heart Failure Drugs market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Reasons to Buy This Report
This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Heart Failure Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
This report will help stakeholders to understand the global industry status and trends of Heart Failure Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
This report stays updated with novel technology integration, features, and the latest developments in the market
This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Heart Failure Drugs industry.
This report helps stakeholders to gain insights into which regions to target globally
This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Heart Failure Drugs.
This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Core Chapters
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Heart Failure Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Heart Failure Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Heart Failure Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
1 PREFACE
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 MARKET OVERVIEW
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global Heart Failure Drugs Market Size (2018-2029) & (US$ Million)
2.2.2 Global Heart Failure Drugs Sales (2018-2029)
2.2.3 Global Heart Failure Drugs Market Average Price (2018-2029)
2.3 Heart Failure Drugs by Type
2.3.1 Market Value Comparison by Type (2018 VS 2022 VS 2029) & (US$ Million)
1.2.2 ACEI
1.2.3 Angiotensin II Receptor Blockers
1.2.4 ARNIs
1.2.5 Beta Blockers
1.2.6 Aldosterone Antagonists
1.2.7 Diuretics
2.4 Heart Failure Drugs by Application
2.4.1 Market Value Comparison by Application (2018 VS 2022 VS 2029) & (US$ Million)
2.4.2 Reduced Ejection Fraction
2.4.3 Preserved Ejection Fraction
3 MARKET COMPETITIVE LANDSCAPE BY MANUFACTURERS
3.1 Global Heart Failure Drugs Market Competitive Situation by Manufacturers (2018 Versus 2022)
3.2 Global Heart Failure Drugs Sales (MT) of Manufacturers (2018-2023)
3.3 Global Heart Failure Drugs Revenue of Manufacturers (2018-2023)
3.4 Global Heart Failure Drugs Average Price by Manufacturers (2018-2023)
3.5 Global Heart Failure Drugs Industry Ranking, 2021 VS 2022 VS 2023
3.6 Global Manufacturers of Heart Failure Drugs, Manufacturing Sites & Headquarters
3.7 Global Manufacturers of Heart Failure Drugs, Product Type & Application
3.8 Global Manufacturers of Heart Failure Drugs, Date of Enter into This Industry
3.9 Global Heart Failure Drugs Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition
4 MANUFACTURERS PROFILED
4.1 Novartis
4.1.1 Novartis Company Information
4.1.2 Novartis Business Overview
4.1.3 Novartis Heart Failure Drugs Sales, Revenue and Gross Margin (2018-2023)
4.1.4 Novartis Heart Failure Drugs Product Portfolio
4.1.5 Novartis Recent Developments
4.2 Pfizer
4.2.1 Pfizer Company Information
4.2.2 Pfizer Business Overview
4.2.3 Pfizer Heart Failure Drugs Sales, Revenue and Gross Margin (2018-2023)
4.2.4 Pfizer Heart Failure Drugs Product Portfolio
4.2.5 Pfizer Recent Developments
4.3 AstraZeneca
4.3.1 AstraZeneca Company Information
4.3.2 AstraZeneca Business Overview
4.3.3 AstraZeneca Heart Failure Drugs Sales, Revenue and Gross Margin (2018-2023)
4.3.4 AstraZeneca Heart Failure Drugs Product Portfolio
4.3.5 AstraZeneca Recent Developments
4.4 Hikma
4.4.1 Hikma Company Information
4.4.2 Hikma Business Overview
4.4.3 Hikma Heart Failure Drugs Sales, Revenue and Gross Margin (2018-2023)
4.4.4 Hikma Heart Failure Drugs Product Portfolio
4.4.5 Hikma Recent Developments
4.5 Teva
4.5.1 Teva Company Information
4.5.2 Teva Business Overview
4.5.3 Teva Heart Failure Drugs Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Teva Heart Failure Drugs Product Portfolio
6.5.5 Teva Recent Developments
4.6 Cipla
4.6.1 Cipla Company Information
4.6.2 Cipla Business Overview
4.6.3 Cipla Heart Failure Drugs Sales, Revenue and Gross Margin (2018-2023)
4.6.4 Cipla Heart Failure Drugs Product Portfolio
4.6.5 Cipla Recent Developments
4.7 Merck & Co.
4.7.1 Merck & Co. Company Information
4.7.2 Merck & Co. Business Overview
4.7.3 Merck & Co. Heart Failure Drugs Sales, Revenue and Gross Margin (2018-2023)
4.7.4 Merck & Co. Heart Failure Drugs Product Portfolio
4.7.5 Merck & Co. Recent Developments
6.8 Amgen
4.8.1 Amgen Company Information
4.8.2 Amgen Business Overview
4.8.3 Amgen Heart Failure Drugs Sales, Revenue and Gross Margin (2018-2023)
4.8.4 Amgen Heart Failure Drugs Product Portfolio
4.8.5 Amgen Recent Developments
4.9 Roche
4.9.1 Roche Company Information
4.9.2 Roche Business Overview
4.9.3 Roche Heart Failure Drugs Sales, Revenue and Gross Margin (2018-2023)
4.9.4 Roche Heart Failure Drugs Product Portfolio
4.9.5 Roche Recent Developments
4.10 Sun Pharma
4.10.1 Sun Pharma Company Information
4.10.2 Sun Pharma Business Overview
4.10.3 Sun Pharma Heart Failure Drugs Sales, Revenue and Gross Margin (2018-2023)
4.10.4 Sun Pharma Heart Failure Drugs Product Portfolio
4.10.5 Sun Pharma Recent Developments
6.11 Mylan
6.11.1 Mylan Company Information
6.11.2 Mylan Heart Failure Drugs Business Overview
6.11.3 Mylan Heart Failure Drugs Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Mylan Heart Failure Drugs Product Portfolio
6.11.5 Mylan Recent Developments
5 GLOBAL HEART FAILURE DRUGS MARKET SCENARIO BY REGION
5.1 Global Heart Failure Drugs Market Size by Region: 2018 VS 2022 VS 2029
5.2 Global Heart Failure Drugs Sales by Region: 2018-2029
5.2.1 Global Heart Failure Drugs Sales by Region: 2018-2023
5.2.2 Global Heart Failure Drugs Sales by Region: 2024-2029
5.3 Global Heart Failure Drugs Revenue by Region: 2018-2029
5.3.1 Global Heart Failure Drugs Revenue by Region: 2018-2023
5.3.2 Global Heart Failure Drugs Revenue by Region: 2024-2029
5.4 North America Heart Failure Drugs Market Facts & Figures by Country
5.4.1 North America Heart Failure Drugs Market Size by Country: 2018 VS 2022 VS 2029
5.4.2 North America Heart Failure Drugs Sales by Country (2018-2029)
5.4.3 North America Heart Failure Drugs Revenue by Country (2018-2029)
5.4.4 U.S.
5.4.5 Canada
5.5 Europe Heart Failure Drugs Market Facts & Figures by Country
5.5.1 Europe Heart Failure Drugs Market Size by Country: 2018 VS 2022 VS 2029
5.5.2 Europe Heart Failure Drugs Sales by Country (2018-2029)
5.5.3 Europe Heart Failure Drugs Revenue by Country (2018-2029)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Russia
5.6 Asia Pacific Heart Failure Drugs Market Facts & Figures by Country
5.6.1 Asia Pacific Heart Failure Drugs Market Size by Country: 2018 VS 2022 VS 2029
5.6.2 Asia Pacific Heart Failure Drugs Sales by Country (2018-2029)
5.6.3 Asia Pacific Heart Failure Drugs Revenue by Country (2018-2029)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 China Taiwan
5.6.10 Indonesia
5.6.11 Thailand
5.6.12 Malaysia
5.7 Latin America Heart Failure Drugs Market Facts & Figures by Country
5.7.1 Latin America Heart Failure Drugs Market Size by Country: 2018 VS 2022 VS 2029
5.7.2 Latin America Heart Failure Drugs Sales by Country (2018-2029)
5.7.3 Latin America Heart Failure Drugs Revenue by Country (2018-2029)
5.7.4 Mexico
5.7.5 Brazil
5.7.6 Argentina
5.8 Middle East and Africa Heart Failure Drugs Market Facts & Figures by Country
5.8.1 Middle East and Africa Heart Failure Drugs Market Size by Country: 2018 VS 2022 VS 2029
5.8.2 Middle East and Africa Heart Failure Drugs Sales by Country (2018-2029)
5.8.3 Middle East and Africa Heart Failure Drugs Revenue by Country (2018-2029)
5.8.4 Turkey
5.8.5 Saudi Arabia
5.8.6 UAE
6 SEGMENT BY TYPE
6.1 Global Heart Failure Drugs Sales by Type (2018-2029)
6.1.1 Global Heart Failure Drugs Sales by Type (2018-2029) & (MT)
6.1.2 Global Heart Failure Drugs Sales Market Share by Type (2018-2029)
6.2 Global Heart Failure Drugs Revenue by Type (2018-2029)
6.2.1 Global Heart Failure Drugs Sales by Type (2018-2029) & (US$ Million)
6.2.2 Global Heart Failure Drugs Revenue Market Share by Type (2018-2029)
6.3 Global Heart Failure Drugs Price by Type (2018-2029)
7 SEGMENT BY APPLICATION
7.1 Global Heart Failure Drugs Sales by Application (2018-2029)
7.1.1 Global Heart Failure Drugs Sales by Application (2018-2029) & (MT)
7.1.2 Global Heart Failure Drugs Sales Market Share by Application (2018-2029)
7.2 Global Heart Failure Drugs Revenue by Application (2018-2029)
6.2.1 Global Heart Failure Drugs Sales by Application (2018-2029) & (US$ Million)
6.2.2 Global Heart Failure Drugs Revenue Market Share by Application (2018-2029)
7.3 Global Heart Failure Drugs Price by Application (2018-2029)
8 VALUE CHAIN AND SALES CHANNELS ANALYSIS OF THE MARKET
8.1 Heart Failure Drugs Value Chain Analysis
8.1.1 Heart Failure Drugs Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 Heart Failure Drugs Production Mode & Process
8.2 Heart Failure Drugs Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 Heart Failure Drugs Distributors
8.2.3 Heart Failure Drugs Customers
9 GLOBAL HEART FAILURE DRUGS ANALYZING MARKET DYNAMICS
9.1 Heart Failure Drugs Industry Trends
9.2 Heart Failure Drugs Industry Drivers
9.3 Heart Failure Drugs Industry Opportunities and Challenges
9.4 Heart Failure Drugs Industry Restraints
10 REPORT CONCLUSION
11 DISCLAIMER
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 MARKET OVERVIEW
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global Heart Failure Drugs Market Size (2018-2029) & (US$ Million)
2.2.2 Global Heart Failure Drugs Sales (2018-2029)
2.2.3 Global Heart Failure Drugs Market Average Price (2018-2029)
2.3 Heart Failure Drugs by Type
2.3.1 Market Value Comparison by Type (2018 VS 2022 VS 2029) & (US$ Million)
1.2.2 ACEI
1.2.3 Angiotensin II Receptor Blockers
1.2.4 ARNIs
1.2.5 Beta Blockers
1.2.6 Aldosterone Antagonists
1.2.7 Diuretics
2.4 Heart Failure Drugs by Application
2.4.1 Market Value Comparison by Application (2018 VS 2022 VS 2029) & (US$ Million)
2.4.2 Reduced Ejection Fraction
2.4.3 Preserved Ejection Fraction
3 MARKET COMPETITIVE LANDSCAPE BY MANUFACTURERS
3.1 Global Heart Failure Drugs Market Competitive Situation by Manufacturers (2018 Versus 2022)
3.2 Global Heart Failure Drugs Sales (MT) of Manufacturers (2018-2023)
3.3 Global Heart Failure Drugs Revenue of Manufacturers (2018-2023)
3.4 Global Heart Failure Drugs Average Price by Manufacturers (2018-2023)
3.5 Global Heart Failure Drugs Industry Ranking, 2021 VS 2022 VS 2023
3.6 Global Manufacturers of Heart Failure Drugs, Manufacturing Sites & Headquarters
3.7 Global Manufacturers of Heart Failure Drugs, Product Type & Application
3.8 Global Manufacturers of Heart Failure Drugs, Date of Enter into This Industry
3.9 Global Heart Failure Drugs Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition
4 MANUFACTURERS PROFILED
4.1 Novartis
4.1.1 Novartis Company Information
4.1.2 Novartis Business Overview
4.1.3 Novartis Heart Failure Drugs Sales, Revenue and Gross Margin (2018-2023)
4.1.4 Novartis Heart Failure Drugs Product Portfolio
4.1.5 Novartis Recent Developments
4.2 Pfizer
4.2.1 Pfizer Company Information
4.2.2 Pfizer Business Overview
4.2.3 Pfizer Heart Failure Drugs Sales, Revenue and Gross Margin (2018-2023)
4.2.4 Pfizer Heart Failure Drugs Product Portfolio
4.2.5 Pfizer Recent Developments
4.3 AstraZeneca
4.3.1 AstraZeneca Company Information
4.3.2 AstraZeneca Business Overview
4.3.3 AstraZeneca Heart Failure Drugs Sales, Revenue and Gross Margin (2018-2023)
4.3.4 AstraZeneca Heart Failure Drugs Product Portfolio
4.3.5 AstraZeneca Recent Developments
4.4 Hikma
4.4.1 Hikma Company Information
4.4.2 Hikma Business Overview
4.4.3 Hikma Heart Failure Drugs Sales, Revenue and Gross Margin (2018-2023)
4.4.4 Hikma Heart Failure Drugs Product Portfolio
4.4.5 Hikma Recent Developments
4.5 Teva
4.5.1 Teva Company Information
4.5.2 Teva Business Overview
4.5.3 Teva Heart Failure Drugs Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Teva Heart Failure Drugs Product Portfolio
6.5.5 Teva Recent Developments
4.6 Cipla
4.6.1 Cipla Company Information
4.6.2 Cipla Business Overview
4.6.3 Cipla Heart Failure Drugs Sales, Revenue and Gross Margin (2018-2023)
4.6.4 Cipla Heart Failure Drugs Product Portfolio
4.6.5 Cipla Recent Developments
4.7 Merck & Co.
4.7.1 Merck & Co. Company Information
4.7.2 Merck & Co. Business Overview
4.7.3 Merck & Co. Heart Failure Drugs Sales, Revenue and Gross Margin (2018-2023)
4.7.4 Merck & Co. Heart Failure Drugs Product Portfolio
4.7.5 Merck & Co. Recent Developments
6.8 Amgen
4.8.1 Amgen Company Information
4.8.2 Amgen Business Overview
4.8.3 Amgen Heart Failure Drugs Sales, Revenue and Gross Margin (2018-2023)
4.8.4 Amgen Heart Failure Drugs Product Portfolio
4.8.5 Amgen Recent Developments
4.9 Roche
4.9.1 Roche Company Information
4.9.2 Roche Business Overview
4.9.3 Roche Heart Failure Drugs Sales, Revenue and Gross Margin (2018-2023)
4.9.4 Roche Heart Failure Drugs Product Portfolio
4.9.5 Roche Recent Developments
4.10 Sun Pharma
4.10.1 Sun Pharma Company Information
4.10.2 Sun Pharma Business Overview
4.10.3 Sun Pharma Heart Failure Drugs Sales, Revenue and Gross Margin (2018-2023)
4.10.4 Sun Pharma Heart Failure Drugs Product Portfolio
4.10.5 Sun Pharma Recent Developments
6.11 Mylan
6.11.1 Mylan Company Information
6.11.2 Mylan Heart Failure Drugs Business Overview
6.11.3 Mylan Heart Failure Drugs Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Mylan Heart Failure Drugs Product Portfolio
6.11.5 Mylan Recent Developments
5 GLOBAL HEART FAILURE DRUGS MARKET SCENARIO BY REGION
5.1 Global Heart Failure Drugs Market Size by Region: 2018 VS 2022 VS 2029
5.2 Global Heart Failure Drugs Sales by Region: 2018-2029
5.2.1 Global Heart Failure Drugs Sales by Region: 2018-2023
5.2.2 Global Heart Failure Drugs Sales by Region: 2024-2029
5.3 Global Heart Failure Drugs Revenue by Region: 2018-2029
5.3.1 Global Heart Failure Drugs Revenue by Region: 2018-2023
5.3.2 Global Heart Failure Drugs Revenue by Region: 2024-2029
5.4 North America Heart Failure Drugs Market Facts & Figures by Country
5.4.1 North America Heart Failure Drugs Market Size by Country: 2018 VS 2022 VS 2029
5.4.2 North America Heart Failure Drugs Sales by Country (2018-2029)
5.4.3 North America Heart Failure Drugs Revenue by Country (2018-2029)
5.4.4 U.S.
5.4.5 Canada
5.5 Europe Heart Failure Drugs Market Facts & Figures by Country
5.5.1 Europe Heart Failure Drugs Market Size by Country: 2018 VS 2022 VS 2029
5.5.2 Europe Heart Failure Drugs Sales by Country (2018-2029)
5.5.3 Europe Heart Failure Drugs Revenue by Country (2018-2029)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Russia
5.6 Asia Pacific Heart Failure Drugs Market Facts & Figures by Country
5.6.1 Asia Pacific Heart Failure Drugs Market Size by Country: 2018 VS 2022 VS 2029
5.6.2 Asia Pacific Heart Failure Drugs Sales by Country (2018-2029)
5.6.3 Asia Pacific Heart Failure Drugs Revenue by Country (2018-2029)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 China Taiwan
5.6.10 Indonesia
5.6.11 Thailand
5.6.12 Malaysia
5.7 Latin America Heart Failure Drugs Market Facts & Figures by Country
5.7.1 Latin America Heart Failure Drugs Market Size by Country: 2018 VS 2022 VS 2029
5.7.2 Latin America Heart Failure Drugs Sales by Country (2018-2029)
5.7.3 Latin America Heart Failure Drugs Revenue by Country (2018-2029)
5.7.4 Mexico
5.7.5 Brazil
5.7.6 Argentina
5.8 Middle East and Africa Heart Failure Drugs Market Facts & Figures by Country
5.8.1 Middle East and Africa Heart Failure Drugs Market Size by Country: 2018 VS 2022 VS 2029
5.8.2 Middle East and Africa Heart Failure Drugs Sales by Country (2018-2029)
5.8.3 Middle East and Africa Heart Failure Drugs Revenue by Country (2018-2029)
5.8.4 Turkey
5.8.5 Saudi Arabia
5.8.6 UAE
6 SEGMENT BY TYPE
6.1 Global Heart Failure Drugs Sales by Type (2018-2029)
6.1.1 Global Heart Failure Drugs Sales by Type (2018-2029) & (MT)
6.1.2 Global Heart Failure Drugs Sales Market Share by Type (2018-2029)
6.2 Global Heart Failure Drugs Revenue by Type (2018-2029)
6.2.1 Global Heart Failure Drugs Sales by Type (2018-2029) & (US$ Million)
6.2.2 Global Heart Failure Drugs Revenue Market Share by Type (2018-2029)
6.3 Global Heart Failure Drugs Price by Type (2018-2029)
7 SEGMENT BY APPLICATION
7.1 Global Heart Failure Drugs Sales by Application (2018-2029)
7.1.1 Global Heart Failure Drugs Sales by Application (2018-2029) & (MT)
7.1.2 Global Heart Failure Drugs Sales Market Share by Application (2018-2029)
7.2 Global Heart Failure Drugs Revenue by Application (2018-2029)
6.2.1 Global Heart Failure Drugs Sales by Application (2018-2029) & (US$ Million)
6.2.2 Global Heart Failure Drugs Revenue Market Share by Application (2018-2029)
7.3 Global Heart Failure Drugs Price by Application (2018-2029)
8 VALUE CHAIN AND SALES CHANNELS ANALYSIS OF THE MARKET
8.1 Heart Failure Drugs Value Chain Analysis
8.1.1 Heart Failure Drugs Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 Heart Failure Drugs Production Mode & Process
8.2 Heart Failure Drugs Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 Heart Failure Drugs Distributors
8.2.3 Heart Failure Drugs Customers
9 GLOBAL HEART FAILURE DRUGS ANALYZING MARKET DYNAMICS
9.1 Heart Failure Drugs Industry Trends
9.2 Heart Failure Drugs Industry Drivers
9.3 Heart Failure Drugs Industry Opportunities and Challenges
9.4 Heart Failure Drugs Industry Restraints
10 REPORT CONCLUSION
11 DISCLAIMER
